Allison M. Bock
( out of 14 reviews )

Allison M. Bock, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her residency training at University of Colorado and fellowship training in hematology/oncology at Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 14 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    January 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bock was bery helpful to us at a difficult time. She was empathetic with us. She is very knowledgeable and very positive about our treatment.

    January 20, 2024
    HUNTSMAN CANCER CENTER

    She is a very good doctor

    January 05, 2024
    HUNTSMAN CANCER CENTER

    Knowledgeable and caring

    December 23, 2023
    HUNTSMAN CANCER CENTER

    Because of the above: listening carefully, treating me with respect, explaining things, etc., I would recommend Allison Bock to anyone needing her care.

    December 22, 2023
    HUNTSMAN CANCER CENTER

    Dr Bock was incredible. I am glad I found her to help me navigate CLL.

    October 19, 2023
    HUNTSMAN CANCER CENTER

    Dr. Bock explained the tests that she was ordering and why. She also let me know that we could start treatment in January after the holidays, which was good to know.

    October 11, 2023
    HUNTSMAN CANCER CENTER

    Our first meeting. Had done her homework on my many past treatments and was well prepared to discuss my care going forward.

    October 04, 2023
    HUNTSMAN CANCER CENTER

    Knowledgeable with my situation and relieved my anxiety.

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her residency training at University of Colorado and fellowship training in hematology/oncology at Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - Mayo Clinic Fellow
    Internal Medicine - University of Colorado School of Medicine Resident
    Professional Medical Medicine; Global Health Pathway - Medical College of Wisconsin M.D.
    Genetics, Cell Biology and Development; minor in Psychology - University of Minnesota - Twin Cities B.S.

    Selected Publications

    Journal Article

    1. Hines AS, Koster MJ, Bock AR, Go RS, Warrington KJ, Olteanu H, Lasho TL, Patnaik MM, Reichard KK (2022). Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology (Oxford), 62(12), 3947-3951. (Read full article)
    2. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv, 7(21), 6381-6394. (Read full article)
    3. Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J, 13(1), 169. (Read full article)
    4. Wenzl K, Stokes M, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ (2023). Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL. (Read full article)
    5. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A (2021). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood, 139(8), 1208-1221. (Read full article)
    6. Simpson HM, Bock A, Cervantes L (2021). Policy in clinical practice: Emergency Medicaid and access to allogeneic stem cell transplant for undocumented immigrants. J Hosp Med, 17(1), 50-53. (Read full article)
    7. Canfield GS, Bock A, Mann S, Zimmer S, Somerset H, Franco-Paredes C, Wilson CC, Metter RB (2020). A 31-year-old Micronesian Man With Shoulder Fungating Mass. Clin Infect Dis, 70(5), 973-975. (Read full article)
    8. Bock AM, Brunmeier A, Wichman CL, Bergl PA (2017). Encephalopathy With Psychosis Following Group A Streptococcal Sepsis-An Immune-Mediated Phenomenon? Psychosomatics, 58(5), 551-555. (Read full article)
    9. Bock AM, LeVeque M, Camitta B, Talano JA (2016). Successful treatment of recurrent CNS disease post-bone marrow transplant in children with familial hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 63(12), 2154-2158. (Read full article)
    10. Bock A, Chintamaneni K, Rein L, Frazer T, Kayastha G, MacKinney T (2016). Improving pneumococcal vaccination rates of medical inpatients in urban Nepal using quality improvement measures. BMJ Qual Improv Rep, 5(1). (Read full article)
    11. Knorr DA, Bock A, Brentjens RJ, Kaufman DS (2013). Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem Cells Dev, 22(13), 1861-9. (Read full article)
    12. Bock AM, Knorr D, Kaufman DS (2013). Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). J Vis Exp, (74), e50337. (Read full article)
    13. Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ (2012). Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant, 19(1), 102-8. (Read full article)

    Review

    1. Bock AM, Nowakowski GS, Wang Y (2022). Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. [Review]. Curr Treat Options Oncol, 23(2), 155-170. (Read full article)

    Letter

    1. Ng WL, Wang Y, Bock AM, Jevremovic D, Wang ML, Nowakowski GS (2023). Review of management options for mantle cell lymphoma in pregnancy. [Letter to the editor]. Leuk Lymphoma, 64(6), 1194-1198. (Read full article)
    2. Bock AM, Pollyea DA (2020). Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemia. [Letter to the editor]. Am J Hematol. (Read full article)

  • News & Podcasts